Allergan Can't Kick Investor Suit Over $600M Botox Settlement
A Delaware judge on Monday kept alive a shareholder derivative suit seeking to hold Botox manufacturer Allergan Inc.'s board liable for a $600 million settlement with the U.S. Department of Justice...To view the full article, register now.
Already a subscriber? Click here to view full article